Table 3.
Antifungal therapy administered and 30-day crude mortality rate in paediatric patients with candidemia, Alfred I. duPont Hospital for Children, 2000–2009
| Cohort n = 106 |
Oncologic n = 14 (13.2%) |
Non-oncologic n = 92 (86.8%) |
Crude mortality n (%) |
|
|---|---|---|---|---|
| Any antifungal agent | 103 (97%) | 12 (86%) | 91 (99%) | 12 (12%) |
| Fluconazole | 47 (46%) | 5 (35.7%) | 42 (46%) | 3 (6%) |
| Amphotericin B | 16 (15%) | 2 (14%) | 14 (15%) | 2 (13%) |
| Voriconazole | 5 (5%) | 1 | 4 | 3 (60%) |
|
| ||||
| Combination therapy | ||||
|
| ||||
| Fluconazole – echinocandins | 4 (4%) | – | 4 | – |
| Fluconazole – Amphotericin B | 31 (29%) | 4 (29%) | 27 (29%) | 4 (13%) |